Explore how Aurigene Services successfully developed an innovative oral formulation to support a 90-day repeated dose toxicity study of a poorly bioavailable, high-dose (3 g) emetic compound in dogs. Faced with challenges including low oral absorption and gastric irritation from conventional suspensions, Aurigene scientists designed an optimized enteric solid dispersion that enhanced intestinal uptake while preventing emesis. Through careful selection of excipients, enteric polymers, and precipitation inhibitors, the team achieved required systemic exposure without adverse effects over the chronic toxicology study duration. This case highlights Aurigene’s deep expertise in formulation development, preclinical toxicology support, and ability to solve complex bioavailability issues to meet GLP study requirements.
https://www.aurigeneservices.com/case-studies/delivering-3-g-dose-emetic-and-poorly-bioavailable-compound-90-days-repeated-dose-toxicity-studies
